ReviewEye (London, England)2023
Giant cell arteritis: reviewing the advancing diagnostics and management.
Review in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Recognition of giant cell arteritis and calcified carotid artery atheromas in dental practice: systematic review and meta-analysis.Clinical oral investigations · 2026Pooled it
- Ultrasound, PET/CT or temporal artery biopsy for giant cell arteritis? A prospective diagnostic accuracy study (the GAME-study).Acta ophthalmologica · 2026Article
- Orofacial symptoms and diagnostic pathways in patients with giant cell arteritis (GCA): a retrospective case series from a dental perspective.BMC oral health · 2026Article
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- Posterior ischemic optic neuropathy as the main manifestation of giant cell arteritis: a case-based literature review.Reumatologia · 2026Article
- Atypical Oral Presentation of Giant Cell Arteritis With Subsequent Middle Cerebral Artery Involvement.Cureus · 2025Article
- Ocular Manifestations of Giant Cell Arteritis.Advances in ophthalmology and optometry · 2025Article
- Soluble Co-Inhibitory Immune Checkpoint Molecules Are Increased in Patients With Polymyalgia Rheumatica Without Significant Correlations With Clinical Status: A Case-Control Study.ACR open rheumatology · 2025Article
- Utilising multiple discharge coding will improve identification of patients with giant cell arteritis: a retrospective analysis of a hospital discharge dataset.Rheumatology international · 2025Article
- Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review.Immunity, inflammation and disease · 2025Review
- Methotrexate-Associated Lymphoproliferative Disorder in a Patient with Polymyalgia Rheumatica Presenting with Double Vision.Neuro-ophthalmology (Aeolus Press) · 2025Article
- Article
- A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement: A Case Report From the National Multiple Sclerosis Society Case Conference Proceedings.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- The impact of histopathological criteria for definite vasculitis in giant cell arteritis: retrospective analysis of temporal artery biopsies.Rheumatology international · 2024Article
- Deep Learning to Discriminate Arteritic From Nonarteritic Ischemic Optic Neuropathy on Color Images.JAMA ophthalmology · 2024Article
- A two sample mendelian randomization analysis investigates causal effects between gut microbiome and immune related Vasculitis.Scientific reports · 2024Article
- Central Nervous System Involvement in Systemic Autoimmune Rheumatic Diseases-Diagnosis and Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Article
- The first giant cell arteritis hospital quality standards (GHOST).Eye (London, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant Cell Arteritis (GCA) is well known to be a critical ischaemic disease that requires immediate medical recognition to initiate treatment and where one in five people still suffer visual loss. The immunopathophysiology has continued to be characterised, and the influencing of ageing in the development of GCA is beginning to be understood. Recent national and international guidelines have supported the directed use of cranial ultrasound to reduce diagnostic delay and improve clinical outcomes. Immediate high dose glucocorticoids remain the standard emergency treatment for GCA, with a number of targeted agents that have been shown in clinical trials to have superior clinical efficacy and steroid sparing effects. The aim of this review was to present the latest advances in GCA that have the potential to influence routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.